Respiratory symptoms and inflammatory responses to Difflam throat-spray intervention in half-marathon runners

A randomised controlled trial

A. J. Cox, M. Gleeson, D. B. Pyne, P. U. Saunders, R. Callister, P. A. Fricker

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Objective: In this study, the effects of Difflam Forte Antiinflammatory Throat Spray on the incidence of upper respiratory symptoms (URS) and inflammatory responses after a half-marathon race were investigated. Design and setting: Double-blind placebo-controlled randomised trial conducted in association with a half-marathon event. Participants: 45 well-trained half-marathon runners. Interventions: Difflam (n = 25) or placebo (n = 20) throat sprays were self-administered three times daily for 1 week before and 2 weeks after the race. Main outcome measures: Self-reported respiratory symptoms; plasma prostaglandin E2, myeloperoxidase, interleukin (IL) 6, IL8, IL10 and IL1 receptor antagonist (IL1ra) concentrations; and salivary myeloperoxidase and L6 concentrations. Results: All subjects completed the intervention without reporting any adverse events. The proportion of athletes reporting URS was not substantially different between Difflam (52%) and placebo (56%) groups (p = 0.82). However, symptom severity scores were ∼29% lower during Difflam treatment (4.7 (7.4) vs 6.6 (9.6)) AU). Postexercise responses in plasma inflammatory markers did not differ substantially between Difflam and placebo groups. Post-race increases in salivary myeloperoxidase (∼63%; trivial to moderate difference; p = 0.13) and salivary IL6 (∼50%; trivial to moderate difference; p = 0.25) were greater in the Difflam group. Conclusions: Prophylactic use of the Difflam reduced the severity, but not the frequency, of URS among half-marathon runners. Post-race increases in systemic inflammatory markers were not altered by Difflam use, but markers of local inflammation (salivary myeloperoxidase and IL6) were augmented in the Difflam compared with the placebo group.

Original languageEnglish
Pages (from-to)127-133
Number of pages7
JournalBritish Journal of Sports Medicine
Volume44
Issue number2
DOIs
Publication statusPublished - 1 Feb 2010
Externally publishedYes

Fingerprint

Benzydamine
Pharynx
Randomized Controlled Trials
Placebos
Peroxidase
Interleukin-6
Interleukin-8 Receptors
Interleukin-6 Receptors
Interleukin-1 Receptors
Dinoprostone
Athletes
Interleukin-10
Anti-Inflammatory Agents
Outcome Assessment (Health Care)

Cite this

@article{00b3f04ea7b6487b8ab9473ae4940b2f,
title = "Respiratory symptoms and inflammatory responses to Difflam throat-spray intervention in half-marathon runners: A randomised controlled trial",
abstract = "Objective: In this study, the effects of Difflam Forte Antiinflammatory Throat Spray on the incidence of upper respiratory symptoms (URS) and inflammatory responses after a half-marathon race were investigated. Design and setting: Double-blind placebo-controlled randomised trial conducted in association with a half-marathon event. Participants: 45 well-trained half-marathon runners. Interventions: Difflam (n = 25) or placebo (n = 20) throat sprays were self-administered three times daily for 1 week before and 2 weeks after the race. Main outcome measures: Self-reported respiratory symptoms; plasma prostaglandin E2, myeloperoxidase, interleukin (IL) 6, IL8, IL10 and IL1 receptor antagonist (IL1ra) concentrations; and salivary myeloperoxidase and L6 concentrations. Results: All subjects completed the intervention without reporting any adverse events. The proportion of athletes reporting URS was not substantially different between Difflam (52{\%}) and placebo (56{\%}) groups (p = 0.82). However, symptom severity scores were ∼29{\%} lower during Difflam treatment (4.7 (7.4) vs 6.6 (9.6)) AU). Postexercise responses in plasma inflammatory markers did not differ substantially between Difflam and placebo groups. Post-race increases in salivary myeloperoxidase (∼63{\%}; trivial to moderate difference; p = 0.13) and salivary IL6 (∼50{\%}; trivial to moderate difference; p = 0.25) were greater in the Difflam group. Conclusions: Prophylactic use of the Difflam reduced the severity, but not the frequency, of URS among half-marathon runners. Post-race increases in systemic inflammatory markers were not altered by Difflam use, but markers of local inflammation (salivary myeloperoxidase and IL6) were augmented in the Difflam compared with the placebo group.",
author = "Cox, {A. J.} and M. Gleeson and Pyne, {D. B.} and Saunders, {P. U.} and R. Callister and Fricker, {P. A.}",
year = "2010",
month = "2",
day = "1",
doi = "10.1136/bjsm.2008.048298",
language = "English",
volume = "44",
pages = "127--133",
journal = "British Journal of Sports Medicine",
issn = "0306-3674",
publisher = "BMJ Publishing Group",
number = "2",

}

Respiratory symptoms and inflammatory responses to Difflam throat-spray intervention in half-marathon runners : A randomised controlled trial. / Cox, A. J.; Gleeson, M.; Pyne, D. B.; Saunders, P. U.; Callister, R.; Fricker, P. A.

In: British Journal of Sports Medicine, Vol. 44, No. 2, 01.02.2010, p. 127-133.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Respiratory symptoms and inflammatory responses to Difflam throat-spray intervention in half-marathon runners

T2 - A randomised controlled trial

AU - Cox, A. J.

AU - Gleeson, M.

AU - Pyne, D. B.

AU - Saunders, P. U.

AU - Callister, R.

AU - Fricker, P. A.

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Objective: In this study, the effects of Difflam Forte Antiinflammatory Throat Spray on the incidence of upper respiratory symptoms (URS) and inflammatory responses after a half-marathon race were investigated. Design and setting: Double-blind placebo-controlled randomised trial conducted in association with a half-marathon event. Participants: 45 well-trained half-marathon runners. Interventions: Difflam (n = 25) or placebo (n = 20) throat sprays were self-administered three times daily for 1 week before and 2 weeks after the race. Main outcome measures: Self-reported respiratory symptoms; plasma prostaglandin E2, myeloperoxidase, interleukin (IL) 6, IL8, IL10 and IL1 receptor antagonist (IL1ra) concentrations; and salivary myeloperoxidase and L6 concentrations. Results: All subjects completed the intervention without reporting any adverse events. The proportion of athletes reporting URS was not substantially different between Difflam (52%) and placebo (56%) groups (p = 0.82). However, symptom severity scores were ∼29% lower during Difflam treatment (4.7 (7.4) vs 6.6 (9.6)) AU). Postexercise responses in plasma inflammatory markers did not differ substantially between Difflam and placebo groups. Post-race increases in salivary myeloperoxidase (∼63%; trivial to moderate difference; p = 0.13) and salivary IL6 (∼50%; trivial to moderate difference; p = 0.25) were greater in the Difflam group. Conclusions: Prophylactic use of the Difflam reduced the severity, but not the frequency, of URS among half-marathon runners. Post-race increases in systemic inflammatory markers were not altered by Difflam use, but markers of local inflammation (salivary myeloperoxidase and IL6) were augmented in the Difflam compared with the placebo group.

AB - Objective: In this study, the effects of Difflam Forte Antiinflammatory Throat Spray on the incidence of upper respiratory symptoms (URS) and inflammatory responses after a half-marathon race were investigated. Design and setting: Double-blind placebo-controlled randomised trial conducted in association with a half-marathon event. Participants: 45 well-trained half-marathon runners. Interventions: Difflam (n = 25) or placebo (n = 20) throat sprays were self-administered three times daily for 1 week before and 2 weeks after the race. Main outcome measures: Self-reported respiratory symptoms; plasma prostaglandin E2, myeloperoxidase, interleukin (IL) 6, IL8, IL10 and IL1 receptor antagonist (IL1ra) concentrations; and salivary myeloperoxidase and L6 concentrations. Results: All subjects completed the intervention without reporting any adverse events. The proportion of athletes reporting URS was not substantially different between Difflam (52%) and placebo (56%) groups (p = 0.82). However, symptom severity scores were ∼29% lower during Difflam treatment (4.7 (7.4) vs 6.6 (9.6)) AU). Postexercise responses in plasma inflammatory markers did not differ substantially between Difflam and placebo groups. Post-race increases in salivary myeloperoxidase (∼63%; trivial to moderate difference; p = 0.13) and salivary IL6 (∼50%; trivial to moderate difference; p = 0.25) were greater in the Difflam group. Conclusions: Prophylactic use of the Difflam reduced the severity, but not the frequency, of URS among half-marathon runners. Post-race increases in systemic inflammatory markers were not altered by Difflam use, but markers of local inflammation (salivary myeloperoxidase and IL6) were augmented in the Difflam compared with the placebo group.

UR - http://www.scopus.com/inward/record.url?scp=76949086619&partnerID=8YFLogxK

U2 - 10.1136/bjsm.2008.048298

DO - 10.1136/bjsm.2008.048298

M3 - Review article

VL - 44

SP - 127

EP - 133

JO - British Journal of Sports Medicine

JF - British Journal of Sports Medicine

SN - 0306-3674

IS - 2

ER -